ReviewJournal of the American Heart Association2026
Ketogenic Diets and Low-Density Lipoprotein Cholesterol in Adults With Normal Weight: An Emerging Clinical Challenge.
Review in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietary Interventions for Hypertriglyceridemia.Current atherosclerosis reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketogenic diets (KDs) are increasingly being adopted by adults with normal body mass index for health and performance-related reasons. Accumulating evidence shows that this population is susceptible to large increases in low-density lipoprotein cholesterol (LDL-C) when consuming KDs, raising concerns about long-term atherosclerotic cardiovascular disease (ASCVD) risk. This review synthesizes current evidence on KD-induced LDL-C elevations among individuals with normal body mass index, explores potential mechanisms underlying this phenotype, and discusses implications for ASCVD risk assessment and clinical management. Short-term clinical trials in healthy individuals with normal body mass index consuming KDs report mean LDL-C increases ranging from 18 to 70 mg/dL. Although it has been proposed that these LDL-C elevations may be benign in otherwise metabolically healthy individuals, supporting evidence is lacking. Strong and consistent evidence supports LDL-C as a causal, cumulative risk factor for ASCVD. However, the long-term ASCVD consequences of KD-induced LDL-C elevation in lean individuals have not been directly studied. Limited coronary imaging data are available in this population, but they do not establish cardiovascular safety. Emerging case reports suggest that moderate carbohydrate reintroduction (50-100 g/d) can substantially reverse KD-induced LDL-C elevations, with further reductions achievable using pharmacologic therapy. Clinicians should be prepared to manage patients who choose to follow KDs, especially those with extreme LDL-C elevation. Regular lipid monitoring and patient-centered risk communication are essential for individuals choosing to follow a KD, particularly those of normal body mass index who may otherwise appear at low ASCVD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.